TELA Bio, Inc. (TELA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 29, 2026, by TELA Bio, Inc., a Delaware corporation. The report discloses preliminary financial results for the quarter ended March 31, 2026, and significant changes to the Board of Directors effective following the 2026 Annual Meeting of Stockholders.
Key Financial Metrics
- Preliminary Revenue: Approximately $19.0 million for the quarter ended March 31, 2026.
- Data Status: Unaudited and preliminary; the quarter-end close process is not yet complete.
- Other Metrics: The filing text does not provide clear values for profit, cash flow, margins, debt, or liquidity for this period.
Material Changes and Governance Updates
The filing details a comprehensive restructuring of the Board of Directors:
- Resignations: Doug Evans (Chairman), Kurt Azarbarzin, Vince Burgess, and Federica O'Brien will retire or resign from the Board and its committees effective immediately following the 2026 Annual Meeting. These departures are not due to any disagreement with the Company.
- New Appointments:
- Joseph Capper: Nominated as a Class I director and to serve as the new Chairman of the Board. He is not expected to qualify as an independent director.
- Guido Neels: Appointed as a Class II director (Compensation and Nominating Committees).
- Guy Nohra: Appointed as a Class III director (Audit and Compensation Committees, expected Chair of Compensation).
- Paul Thomas: Appointed as a Class III director (Audit and Nominating Committees, expected Chair of Nominating).
- Compensation: The Board approved initial equity awards for the new directors, consisting of stock options (17,550 shares) and restricted stock units (11,925 shares), plus cash compensation.
Guidance, Outlook, and Risks
The Company cautions that the preliminary revenue figure of $19.0 million is subject to change upon completion of financial closing procedures. The actual results may differ materially from this estimate. The final audited results will be included in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. No specific forward-looking guidance or risk factors beyond the standard disclaimer regarding preliminary data were provided in this filing.
Investor Verification Checklist
- Verify the final audited revenue and full financial statements in the upcoming Form 10-Q for the quarter ended March 31, 2026.
- Confirm the election of Joseph Capper and the appointment of the new directors at the 2026 Annual Meeting.
- Review the Company's non-employee director compensation policy to understand the full scope of the equity awards granted.
- Monitor for any further disclosures regarding the transition of leadership and strategic direction under the new Board composition.